AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02279303 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Control
Description: Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
Study NCT01348529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet CBT
Description: Internet-delivered cognitive behavioral therapy with therapist support.
Study NCT03747029 — intervention group
Intervention type: OTHER
Intervention: No intervention is provided
Description: No intervention is provided
Study NCT03397901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transverse colostomy
Description: Transverse double-cavity colostomy
Study NCT03174977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Raltegravir
Description: A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
Study NCT01469429 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01469429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00572169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given into the vein (IV) by a continuous infusion through a central catheter
Study NCT00061958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Description: Given IV
Study NCT02015377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High sugar versus low sugar meals
Description: Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
Study NCT01748994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: 30mg per day for four months
Study NCT01748994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01987713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: lifestyle intervention
Description: the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
Study NCT01447628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: intravenous, no active drug
Study NCT04378933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Amber Glasses
Description: Half of the participants will be wearing the amber glasses to see if they can help with sleep onset.
Study NCT04378933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Lens Glasses
Description: Half of the participants will be wearing the clear glasses to see if the glasses help with sleep onset.
Study NCT01447628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intravenous, no active drug
Study NCT01447628 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferinject or CosmoFer
Description: Intravenous, 1000 mg iron
Study NCT01447628 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ferinject or CosmoFer
Description: Intravenous, 1000 mg iron
Study NCT00338026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ECO-4601
Description: Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
Study NCT01777191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Auto-Injector
Description: Administered SC by auto-injector
Study NCT01777191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixekizumab Prefilled Syringe
Description: Administered SC by prefilled syringe
Study NCT02591017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Morphine
Study NCT02591017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ketamine
Study NCT02591017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Study NCT01159418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat (LBH589), Carboplatin and Paclitaxel
Description: 1. Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).~2. Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).~3. Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).~The treatment will be repeated every three weeks until disease progression.
Study NCT03265028 — intervention group
Intervention type: BEHAVIORAL
Intervention: TRACE e-learning
Description: The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
Study NCT02591017 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chitosan
Study NCT01591681 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pump suspension
Description: The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
Study NCT01788163 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: EGFR mutation test
Description: EGFR mutation being tested in tissue and blood
Study NCT04720573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: 50 mcg/kg neostigmine was used under the guidance of TOF monitoring after cessation of anesthesia.
Study NCT01258205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 139
Description: Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
Study NCT04720573 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: 2 mg/kg sugammadex was used under the guidance of TOF monitoring after cessation of anesthesia.
Study NCT01723904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
Study NCT04072965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: balance training
Description: Thirty five females with CAI will be recruited from the Faculty of Physical Therapy, Cairo University by announcements to participate in this study. The participants will be randomly assigned into three groups; (A) Cross Education will receive single leg balance training for the non affected side (n=10), (B) Traditional training will receive single leg balance training for the affected side (n=10), (C) control group will receive no intervention (n=15).
Study NCT02149589 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Study NCT02149589 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Mechanical ventilation
Study NCT03985813 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Screening Wizard
Description: Screening Wizard is a decision support tool to guide the primary care provider to make a referral that reflects patient clinical needs and patient and parental treatment preferences and perceived barriers to treatment.
Study NCT03783559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE
Study NCT03783559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy±target therapy
Description: chemotherapy±target therapy
Study NCT00402779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth daily
Study NCT00402779 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet by mouth daily
Study NCT02494583 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m\^2 IV on Day 1 of each week in 3-week cycles (6 cycle maximum per local country guidelines).
Study NCT03783559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy±target therapy
Description: chemotherapy±target therapy
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-FU
Description: 5-FU 800 mg/m\^2/day IV continuous from Day 1-5 of each 3-week cycle.
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine 1000 mg/m\^2 twice daily by oral tablet on Day 1-14 of each 3-week cycle.
Study NCT02494583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline IV on Day 1 of each week in 3-week cycles for up to 35 cycles (approximately 2 years).
Study NCT00797316 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150 mg or 300 mg taken once daily in oral form
Study NCT00797316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aliskiren
Description: Aliskiren 150 mg or 300 mg taken once daily in oral form
Study NCT00797316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
Study NCT04975113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive neuromuscular exercise program
Description: The exercises to be performed in the following week at the beginning of each week were explained by the researcher physiotherapist on the brochure and given as a home program and continued for a total of 12 weeks. The researcher physiotherapist saw the patients every week and carried out exercise compliance and control.
Study NCT04975113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise and Taping
Description: I taping for accurate positioning of the tissue was applied to the patients to neutralize the patellofemoral joint. During the knee flexion in the supine position, the tape was adhered to the skin with a moderate-to-extreme stretch (50%-75%) . Clinical therapeutic applications of the Kinesio taping methods (Tokyo, Japan: Ken Ikai Co Ltd.). In addition to the patellar taping, correction taping to neutralize the subtalar joint by elevating the midtarsal joint and medial arch was applied. The patients were positioned in prone lying and knee flexion position, the taping was started at the 5th metatarsal level on the dorsal side of the finger and finished extending towards the medial of the tibia . Tapings were renewed at the beginning of each week for 6 weeks.
Study NCT01739465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Description: Photodynamic therapy
Study NCT01016158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Umbilical cord serum eyedrops
Description: 20% umbilical cord serum eye drops 3 to 4 times a day
Study NCT01892020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
Study NCT01892020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic human insulin 50
Description: Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
Study NCT00486577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: significant chronic primary auditory cortex stimulation during the first two weeks
Description: significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
Study NCT00486577 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non significant chronic primary auditory cortex stimulation during the first two weeks
Description: non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
Study NCT02270060 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
Study NCT02270060 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Music Listening
Description: Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
Study NCT02752451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Anatomic Arthroscopy Simulation
Description: Knee arthroscopy training using Cigar Box Arthroscopy Trainer
Study NCT02752451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anatomic Arthroscopy Simulation
Description: Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
Study NCT02752451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-assesment education
Description: Reading material and lecture with only still images about performing diagnostic knee arthroscopy
Study NCT02752451 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-assesment education
Description: Reading material and lecture with only still images about performing diagnostic knee arthroscopy
Study NCT01669343 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Letrozole
Description: Part A Monitor standard of care letrozole use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period. Part B In overweight/obese participants who completed Part A, provide a double dose of letrozole and monitor use for 28 days; measure blood levels of estrogens and vitamin D at start and end of period.
Study NCT02323594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
Study NCT02323594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
Study NCT02323594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir
Description: Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
Study NCT02323594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Description: Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
Study NCT04509531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wise Intervention (SA, ITP and resilience)
Description: The intervention will be based on four general types of change strategies: (1) scientific knowledge, (2) generation of new meanings, (3) commitment through action, and (4) active reflection. This will include activities such as reading scientific information about social behavior and its role in people's well-being and mental health, the meaning of online victimization experiences and ways to react to them, experiences of other young people of their age, and self-persuasion exercises that involve an active commitment to change. Furthermore, it provides a number of strategies to manage everyday conflicts among adolescents. This intervention teaches them new ways to manage these difficulties through different actions (relaxation, distraction, sports, etc.). Finally, they are asked to plan the strategies they will use in the future in the face of some difficulties and to recommend some guidelines for another adolescent who may be going through a similar situation.
Study NCT04509531 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard preventive intervention
Description: The control intervention will involve scientific information and education about internet risks such as sexting and grooming.
Study NCT03699306 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NG tube insertion method
Description: a feeding tube called naso-gastric or NG tube were inserted through nostril inside the stomach randomly by one of three methods mentioned earlier
Study NCT03498534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300Mg Tab
Description: -TST tests will receive isoniazid 300Mg Tab for 6 months
Study NCT03498534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 MG
Description: + TST test will receive isoniazid 300MG Tab for 6 months
Study NCT03498534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid 300 MG
Description: HIV positive patient will receive isoniazid 300MGTab for 6 months
Study NCT03920514 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hCG
Description: Women will be given hCG before or with IUI
Study NCT03855189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate (MF)
Description: Mometasone furoate nasal spray administered as 200 mcg total dose per day for 4 weeks.
Study NCT03855189 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beclomethasone Dipropionate (BDP)
Description: Beclomethasone dipropionate nasal spray administered as 168 mcg twice daily (BID) \[336 mcg total dose per day\] for 4 weeks.
Study NCT04000529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNO155
Description: Capsule
Study NCT03855189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo nasal spray administered for 4 weeks.
Study NCT03855189 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray administered for 4 weeks.
Study NCT01687517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
Study NCT01687517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Seasonal influenza vaccine available for the 2012-2013 vaccine campaign
Description: Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
Study NCT02455986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The StepSmart Challenge
Description: A six month pedometer based intervention designed to increase Physical Activity in school children
Study NCT04000529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Concentrate for solution for infusion
Study NCT04000529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Capsule and tablet
Study NCT03402945 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prevena
Description: Negative-Pressure Wound Management System
Study NCT03495024 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Varenicline
Description: Oral medication approved to facilitate smoking cessation
Study NCT02885233 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Free From Falls Online
Description: Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.